PKC Inhibitors
1 drugsAbout PKC
Protein kinase C (PKC) is a family of serine/threonine kinases involved in cell growth, differentiation, apoptosis, and inflammation. These enzymes play a crucial role in various cellular signaling pathways.
PKC's role in cell signaling makes it a compelling target for drug development, though there is currently no genetic evidence directly linking PKC to specific diseases.
PKC is targeted by one FDA-approved small molecule drug, RYDAPT (Novartis), which has four indications in oncology.
Top PKC Drugs
Novartis is the only company with an approved drug targeting PKC.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges in the target's druggability.
PKC Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PKC, using small molecule modality.
Explore opportunities for novel modalities like antibodies or PROTACs to differentiate from existing therapies.
PKC Clinical Trials 36 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PKC. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 9 | 4 | 3 | 69% |
| Phase 2 | 15 | 7 | 5 | 3 | 58% |
| Phase 3 | 5 | 4 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved PKC drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PKC. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PKC Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval for PKC was RYDAPT in 2017.
The single approval in 2017 indicates a potentially saturated market or challenges in developing successful PKC-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 25 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PKC. A trial counts if an approved drug acting on PKC is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.